UPDATE 1-Marathon Pharma to sell Duchenne drug to PTC Therapeutics
March 16, 2017 at 08:20 AM EDT
March 16 (Reuters) - Marathon Pharmaceuticals LLC, under intense pressure from U.S. lawmakers for the hefty price tag on its Duchenne muscular dystrophy drug, has agreed to sell the rights to the recently-approved treatment to PTC Therapeutics Inc.